Particularly, the identification of serine 325 as the phosphorylation site mediating NFYa degradation recognized a key regulatory molecular switch, as well as a potential target for modulating NFYa activity in metabolic disorders or developmental abnormalities. This evidence concerns the gene NFYA and Other metabolic disease.